About 3SBio (NASDAQ:SSRX)
3SBio Inc. is a biotechnology company in the People's Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
3SBio (NASDAQ:SSRX) Frequently Asked Questions
What is 3SBio's stock symbol?
3SBio trades on the NASDAQ under the ticker symbol "SSRX."
How were 3SBio's earnings last quarter?
3SBio Inc (NASDAQ:SSRX) issued its earnings results on Monday, March, 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.14 by $0.02. The biotechnology company had revenue of $26.30 million for the quarter, compared to the consensus estimate of $25.63 million. View 3SBio's Earnings History.
Who are 3SBio's key executives?
3SBio's management team includes the folowing people:
- Jing Lou, Executive Chairman of the Board, Chief Executive Officer (Age 54)
- Bo Tan, Chief Financial Officer, Executive Vice President, Executive Director (Age 44)
- Fei You, Director - Finance (Age 38)
- Weihonghas Xiao, Chief Operating Officer (Age 48)
- Dongmei Su, Senior Vice President, Executive Director (Age 46)
- Zhenping Zhu MD. Ph.D., Chief Scientific Officer, President - Research & Development (Age 52)
- Bin Huang, Vice President, Executive Director (Age 56)
- Xin Ma, Vice President - Human Resources (Age 51)
- Yongfu Chen, Vice President (Age 60)
- Kevin Liu, Vice President (Age 47)
Has 3SBio been receiving favorable news coverage?
Media coverage about SSRX stock has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. 3SBio earned a media sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.69 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of 3SBio?
Shares of SSRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is 3SBio's stock price today?
One share of SSRX stock can currently be purchased for approximately $16.59.
How big of a company is 3SBio?
3SBio has a market capitalization of $366.10 million.
How can I contact 3SBio?
3SBio's mailing address is No. 3 A1, Road 10 Shenyang Economy & Technology Development Zone, SHENYANG, LIA 110027, China. The biotechnology company can be reached via phone at +86-24-25811820.
MarketBeat Community Rating for 3SBio (SSRX)MarketBeat's community ratings are surveys of what our community members think about 3SBio and other stocks. Vote "Outperform" if you believe SSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SSRX will underperform the S&P 500 over the long term. You may vote once every thirty days.